Drug resistance hampers our capacity to roll back malaria

Clinical Infectious Diseases

Volumn 41, Issue 4 SUPPL., 2005, Pages

  Olliaro, Piero ^a,b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEKIN; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; BIGUANIDE DERIVATIVE; CHLOROQUINE; CHLORPHENOTANE; CHLORPROGUANIL PLUS DAPSONE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; FOLIC ACID ANTAGONIST; HALOFANTRINE; MEFLOQUINE; MOLECULAR MARKER; PYRIMETHAMINE; PYRONARIDINE; QUINIDINE; QUININE; QUINOLONE DERIVATIVE; SULFONAMIDE; SULFONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOPHELES; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ECONOMIC ASPECT; EPIDEMIC; GAMETOCYTE; GENE AMPLIFICATION; GENE MUTATION; HEALTH CARE POLICY; HUMAN; MALARIA; MALARIA CONTROL; MORBIDITY; MORTALITY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FOLIC ACID ANTAGONISTS; GENETIC MARKERS; HUMANS; MALARIA; MUTATION; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; QUINOLINES; RISK FACTORS; TREATMENT OUTCOME;

EID: 23244443547     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430785     Document Type: Review

References (62)

1. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001; 64:1-11.
2. Guerin PJ, Olliaro P, Nosten F, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2002; 2:564-73.
3. Greenwood B, Mutabinwa T. Malaria in 2002. Nature 2002; 415: 670-772.
4. World Health Organization, Roll Back Malaria Department. Available at: http://mosquito.who.int/. Accessed 24 June 2005.
5. Snow RW, Marsh K. New insights into the epidemiology of malaria relevant for disease control. Br Med Bull 1998; 54:293-309.
6. Trape JF, Pison G, Spiegel A, Enel C, Rogier C. Combating malaria in Africa. Trends Parasitol 2002; 18:224-30.
7. Myint HY, Tipmanee P, Nosten F, et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 2004; 98:73-81.
8. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present and future. Lancet Infect Dis 2004; 4:327-36.
9. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 2001; 17:593-7.
10. Snow RW, Eckert E, Teklehaimanot A. Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends Parasitol 2003; 19:363-9.
11. Snow RW, Craig MH, Newton CRJC, Steketee RW. The public health burden of Plasmodium falciparum malaria in Africa: deriving the numbers. Bethesda, MD: Disease Control Priority Project, 2003.
12. Korenromp E. Malaria incidence estimates at country level for the year 2004-proposed estimates and draft report. 11 March 2004. Available at: http://mosquito.who.int/. Accessed 24 June 2005.
13. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214-7.
14. Olliaro PL. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol Ther 2001; 89:207-19.
15. Winstanley P. Modern chemotherapeutic options for malaria. Lancet Infect Dis 2001; 1:1-19.
16. Olliaro PL, Taylor WRJ. Antimalarial compounds: from bench to bedside. J Exp Biol 2003; 206:3753-9.
17. Medicine for Malaria Venture. MMV Projects. Available at: http://www.mmv.org/. Accessed 24 June 2005.
18. White NJ. Why is it that antimalarial drug treatments do not always work? Ann Trop Med Parasitol 1998; 92:449-58.
19. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113: 1084-92.
20. Price RN, Nosten F. Drug resistant falciparum malaria: clinical consequences and strategies for prevention. Drug Resist Updat 2001; 4: 187-96.
21. Winstanley PA, Ward SA, Snow RW. Clinical status and implications of antimalarial drug resistance. Microb Infect 2002; 4:157-64.
22. Hastings IM, D'Alessandro U. Modeling a predictable disaster: the rise and spread of drug-resistant malaria. Parasitol Today 2000; 16:340-7.
23. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41: 1413-22.
24. Mackinnon MJ, Hastings IM. The evolution of multiple drug resistance in malaria parasites. Trans R Soc Trop Med Hyg 1998; 92:188-95.
25. White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc Biol Sci 2003; 270:545-54.
26. Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci 2002; 357:505-19.
27. Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363:9-17.
28. Butcher GA. Antimalarial drugs and the mosquito transmission of Plasmodium. Int J Parasitol 1997; 27:975-87.
29. Sutherland CJ, Alloueche A, Curtis J, et al. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg 2002; 67:578-85.
30. Hill WG, Babiker HA, Ranford-Cartwright LC, Walliker D. Estimation of inbreeding coefficients from genotypic data on multiple alleles, and application to estimation of clonality in malaria parasites. Genet Res 1995; 65:53-61.
31. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004; 305: 1124.
32. Mehlotra RK, Fujioka H, Roepe PD, et al. Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc Natl Acad Sci USA 2001; 98:12689-94.
33. Talisuna AO, Nalunkuma-Kazibwe A, Langi P, et al. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infect Genet Evol 2004; 4:321-7.
34. Kublin JG, Cortese JF, Njunju EM, et al. Reemergence of cholorquine-sensitive Plasmodium falciparum malaria after cessation of cholorquine use in Malawi. J Infect Dis 2003; 187:1870-5.
35. Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004; 9:1241-6.
36. Fidock DA, Nomura T, Cooper RA, Su X, Talley AK, Wellems TE. Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum. Mol Biochem Parasitol 2000; 110:1-10.
37. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770-6.
38. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438-47.
39. Sibley CH, Hyde JE, Sims PF, et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 2001; 17: 582-8.
40. Plowe C, Kublin JG, Doumbo OK. P falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role of clinical resistance to antifolates. Drug Resist Updat 1998; 1:389-96.
41. Wang P, Lee CS, Bayoumi R, et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in large number of field samples of diverse origins. Mol Biochem Parasitol 1997; 89:161-77.
42. Nzila AM, Mberu EK, Sulo J, et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 2000; 44: 991-6.
43. Committee on the Economics of Antimalarial Drugs, Board on Global Health, Institute of Medicine of the National Academies. Saving lives, buying time: economics of malaria drugs in an age of drug resistance. Washington, DC: National Academies Press, 2004.
44. Plowe CV. Monitoring antimalarial drug resistance: making the most of the tools at hand. J Exp Biol 2003; 206:3745-52.
45. World Health Organization (WHO). Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Document no. WHO/HTM/RBM/2003.50. Geneva: WHO, 2003.
46. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18:458-64.
47. Blowland PB, D'Alessandro U, Ringwald P, Watkins WM, eds. Monitoring antimalarial drug resistance. Document no. WHO/CDS/CSR/EPH/2002.17. Geneva: World Health Organization, 2002.
48. Snounou G, Beck HP. The use of PCR genotyping in the assessment of recrudescence or re-infection after antimalarial drug treatment. Parasitol Today 1998; 14:462-7.
49. Greenwood B. The molecular epidemiology of malaria. Trop Med Int Health 2002; 7:1012-21.
50. Stepniewska K, Taylor WRJ, Mayxay M, et al. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 2004; 48:4271-80.
51. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2:209-18.
52. World Health Organization. Global report on the susceptibility of Plasmodium falciparum to antimalarial drugs (1996-2004). WHO/HTM/MAL/2005.1103. Available at: http://www.who.int/malaria/resistance .html. Accessed 24 June 2005.
53. Pukrittayakamee S, Supanaranond W, Looareesuwan S, Vanijanonta S, White NJ. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg 1994; 88:324-7.
54. Taylor WR, Widjaja H, Richie TL, et al. Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg 2001; 64:223-8.
55. Maguire JD, Sumawinata IW, Masbar S, et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002; 360: 58-60.
56. World Health Organization (WHO). Antimalarial drug combination therapy. Document no. WHO/CDS/RBM/2001.35. Geneva: WHO, 2001.
57. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 1999; 41:301-8.
58. Nosten F, Brasseur P. Combination therapy for malaria: the way forward? Drugs 2002; 62:1315-29.
59. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356:297-302.
60. Muheki C, McIntyre D, Barnes KI. Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa. Trop Med Int Health 2004; 9:959-66.
61. Panosian CB. Economic access to effective drugs for falciparum malaria. Clin Infect Dis 2005; 40:713-7.
62. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002; 415:680-5.